A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Platform.

Naubourg, Pierre; El Osta, Marven; Rageot, David; Grunewald, Olivier; Renom, Gilles; Ducoroy, Patrick; Périni, Jean-Marc

Naubourg, Pierre; El Osta, Marven; Rageot, David; Grunewald, Olivier; Renom, Gilles; Ducoroy, Patrick; Périni, Jean-Marc.

Afiliação

Naubourg P; Biomaneo, 22B boulevard Winston Churchill, F-21000 Dijon, France.
El Osta M; Biomaneo, 22B boulevard Winston Churchill, F-21000 Dijon, France.
Rageot D; CLIPP, Clinical Innovation Proteomic Platform, Université de Bourgogne Franche Comté, F-21000 Dijon, France.
Grunewald O; Newborn Screening Laboratory, Biology and Pathology Center, Lille University Medical Centre, F-59000 Lille, France.
Renom G; Newborn Screening Laboratory, Biology and Pathology Center, Lille University Medical Centre, F-59000 Lille, France.
Ducoroy P; Biomaneo, 22B boulevard Winston Churchill, F-21000 Dijon, France.
Périni JM; Newborn Screening Laboratory, Biology and Pathology Center, Lille University Medical Centre, F-59000 Lille, France.

Int J Neonatal Screen ; 5(1): 10, 2019 Mar.

Article em En | MEDLINE | ID: mdl-33072970

Palavras-chave

MALDI-TOF; mass spectrometry; newborn screening; prevention; sickle cell disease; thalassemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google